AORT insider buying and SEC filings, explained
Artivion, Inc. · CIK 784199
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$13.3M
Planned sales (10b5-1)
$4.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 10, 2026 | Sale | Andrew M. Green (SVP, Regulatory and Quality) sold 11,480 shares at about $24.97 ($287K). Holdings down 22% to 40,160 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 11, 2026 |
| Sep 2–3, 2026 | Sale | Andrew M. Green (SVP, Regulatory and Quality) sold 8,003 shares between Sep 2 and Sep 3 at about $27.04 ($216K). Holdings down 13% to 51,640 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 4, 2026 |
| Aug 19, 2026 | Sale | James P Mackin (CEO) sold 70,000 shares at about $28.96 ($2.0M). Holdings down 7% to 877,275 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| Aug 14, 2026 | Sale | Andrew M. Green (SVP, Regulatory and Quality) sold 616 shares at $28.55 ($18K). Holdings down 1% to 59,643 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 17, 2026 |
| Aug 14, 2026 | Sale | Lance A Berry (CFO) sold 715 shares at $28.55 ($20K). Holdings down <1% to 210,112 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 17, 2026 |
| Aug 12, 2026 | Sale | Jean F Holloway (SVP, General Counsel) sold 977 shares at $28.49 ($28K). Holdings down 1% to 184,118 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Jun 11, 2026 | Planned (10b5-1) | Andrew M. Green (SVP, Regulatory and Quality) sold 44,001 shares at about $20.70 ($911K), marked as a 10b5-1 plan trade. Holdings down 42% to 60,259 shares. | SEC filing Filed Jun 15, 2026 |
| Mar 3, 2026 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 901 shares at $37.78 ($34K). Holdings down 1% to 139,088 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 3–4, 2026 | Sale | Jean F Holloway (SVP, General Counsel) sold 12,805 shares between Mar 3 and Mar 4 at about $37.93 ($486K). Holdings down 6% to 185,095 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 2,149 shares at $37.78 ($81K). Holdings down 3% to 60,097 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Sale | John E Davis (Chief Commercial Officer) sold 4,573 shares at $37.78 ($173K). Holdings down 2% to 230,794 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Sale | Lance A Berry (CFO) sold 6,316 shares at $37.78 ($239K). Holdings down 3% to 210,827 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Sale | James P Mackin (CEO) sold 17,887 shares at $37.78 ($676K). Holdings down 2% to 947,275 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 641 shares at $38.02 ($24K). Holdings down <1% to 132,514 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 1,513 shares at $38.02 ($58K). Holdings down 4% to 40,408 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | James P Mackin (CEO) sold 14,911 shares at $38.02 ($567K). Holdings down 2% to 848,214 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Jean F Holloway (SVP, General Counsel) sold 2,183 shares at $38.02 ($83K). Holdings down 1% to 170,105 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | Lance A Berry (CFO) sold 5,178 shares at $38.02 ($197K). Holdings down 3% to 176,269 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Mar 2, 2026 | Sale | John E Davis (Chief Commercial Officer) sold 2,784 shares at $38.02 ($106K). Holdings down 1% to 206,522 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Feb 23–24, 2026 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 2,561 shares between Feb 23 and Feb 24 at about $36.97 ($95K). Holdings down 2% to 127,497 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 3,682 shares between Feb 23 and Feb 24 at about $36.94 ($136K). Holdings down 8% to 41,921 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Sale | Jean F Holloway (SVP, General Counsel) sold 4,747 shares between Feb 23 and Feb 24 at about $36.92 ($175K). Holdings down 3% to 152,203 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Sale | James P Mackin (CEO) sold 34,898 shares between Feb 23 and Feb 24 at about $36.83 ($1.3M). Holdings down 4% to 766,095 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Sale | Lance A Berry (CFO) sold 9,466 shares between Feb 23 and Feb 24 at about $36.69 ($347K). Holdings down 6% to 143,965 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23–24, 2026 | Sale | John E Davis (Chief Commercial Officer) sold 5,848 shares between Feb 23 and Feb 24 at about $36.92 ($216K). Holdings down 3% to 188,868 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Dec 15, 2025 | Sale | John E Davis (Chief Commercial Officer) sold 5,000 shares at $45.11 ($226K). Holdings down 3% to 193,842 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 8, 2025 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 4,572 shares at $44.42 ($203K). Holdings down 3% to 130,058 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 9, 2025 |
| Dec 3, 2025 | Planned (10b5-1) | James P Mackin (CEO) sold 30,921 shares at about $45.46 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 4% to 800,993 shares. | SEC filing Filed Dec 4, 2025 |
| Dec 3, 2025 | Sale | Jean F Holloway (SVP, General Counsel) sold 7,315 shares at $45.30 ($331K). Holdings down 4% to 156,093 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 4, 2025 |
| Dec 2, 2025 | Planned (10b5-1) | James P Mackin (CEO) sold 30,921 shares at about $45.56 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 4% to 800,993 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 20, 2025 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 15,276 shares at about $44.18 ($675K). Holdings down 25% to 44,753 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 24, 2025 |
| Nov 18, 2025 | Sale | Elizabeth A Hoff (Director) sold 4,200 shares at about $45.10 ($189K). Holdings down 13% to 27,189 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
| Nov 17, 2025 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 6,000 shares at about $45.73 ($274K). Holdings down 4% to 135,380 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 18, 2025 |
| Nov 14–17, 2025 | Planned (10b5-1) | Jean F Holloway (SVP, General Counsel) sold 12,787 shares between Nov 14, 2025 and Nov 17, 2025 at about $45.09 ($577K), marked as a 10b5-1 plan trade. Holdings down 7% to 163,408 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 14–17, 2025 | Planned (10b5-1) | John E Davis (Chief Commercial Officer) sold 12,787 shares between Nov 14, 2025 and Nov 17, 2025 at about $44.92 ($574K), marked as a 10b5-1 plan trade. Holdings down 6% to 198,842 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 13, 2025 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 3,482 shares at $45.86 ($160K). Holdings down 2% to 141,380 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Sale | John E Davis (Chief Commercial Officer) sold 6,563 shares at $45.86 ($301K). Holdings down 3% to 198,842 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Sale | James P Mackin (CEO) sold 34,210 shares at $45.86 ($1.6M). Holdings down 4% to 800,993 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Sale | Jean F Holloway (SVP, General Counsel) sold 5,761 shares at $45.86 ($264K). Holdings down 3% to 163,408 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 13, 2025 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 4,993 shares at $45.86 ($229K). Holdings down 8% to 56,641 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 10, 2025 | Sale | Jean F Holloway (SVP, General Counsel) sold 2,960 shares at $44.62 ($132K). Holdings down 2% to 169,169 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | James P Mackin (CEO) sold 17,580 shares at $44.62 ($784K). Holdings down 2% to 835,203 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | John E Davis (Chief Commercial Officer) sold 3,373 shares at $44.62 ($151K). Holdings down 2% to 205,405 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | Amy Horton (VP, Chief Accounting Officer) sold 1,789 shares at $44.62 ($80K). Holdings down 1% to 144,862 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Sale | Marshall S. Stanton (SVP, Clinical & MD Affair) sold 2,566 shares at $44.62 ($114K). Holdings down 4% to 61,634 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 12, 2025 |
34 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AORT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.